Evidence map›Paper›PMID 36282987›Full record

ArticleRevista medica del Instituto Mexicano del Seguro Social2022

[Etiology of bacterial pneumonias in patients with COVID-19].

Ulises Angeles-Garay, Joel Alejandro Hernández-Herrera, Jorge Procopio-Velázquez, Julio Elías Alvarado-Yaah, Isaac Leopoldo González-Cruz

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in Revista medica del Instituto Mexicano del Seguro Social, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ulises Angeles-GarayInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades, División de Medicina Preventiva y Epidemiología Hospitalaria. Ciudad de México, México.ORCID 0000-0002-4338-7669
Joel Alejandro Hernández-HerreraInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades, División de Medicina Preventiva y Epidemiología Hospitalaria. Ciudad de México, México.ORCID 0000-0003-1894-8951
Jorge Procopio-VelázquezInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades, Departamento de Infectología. Ciudad de México, México.ORCID 0000-0002-0709-5474
Julio Elías Alvarado-YaahInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades, Laboratorio Central de Referencia Epidemiológica. Ciudad de México, México.ORCID 0000-0002-7230-9045
Isaac Leopoldo González-CruzInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades, Departamento de Imagenología. Ciudad de México, México.ORCID 0000-0002-3835-1864
Centro Médico Nacional La Raza · MXMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Aggregate bacterial pneumonia plays a fundamental role in mortality of patients hospitalized with COVID-19. Objective: To estimate the association of aggregated bacterial pneumonia with mortality in patients at Hospital Especialidades "La Raza". Material and methods: Analytical cross-sectional study, 252 COVID-19 patients, chest x-ray and culture of bronchial secretion or expectoration. Data taken from the SIOC electronic file and the IZASAlab platform. Results: 252 participants, positive culture, 89 patients, 35.3%, isolation of K. pneumoniae (22.5%), A. baumannii (20.2%), P. aeruginosa (13.5%) and S. aureus (11.2%), antimicrobial resistance 37.1%. 43.7% died, lung damage greater than 50% RMa 2.25 (95% CI 1.01-5.11) p=0.04 against minor lung damage; microorganism in culture RMa 9.04 (95% CI 3.06-26.74) p=0.000; antimicrobial resistance RMa 7.57 (95% CI 1.34-42.79) p=0.02; S. aureus RMa 1.24 (95% CI 0.36-4.23) p=0.73; A. baumannii RMa 3.74 (95% CI 1.41-9.91) p=0.008; K. pneumoniae RMa 4.12 (95% CI 1.55-10.97) p=0.005; and P. aeruginosa RMa 6.89 (95% CI 1.62-17.61) p=0.01. Uncontrolled Diabetes RMa 1.61 (IC95% 1.1-2.9) p=0.018. Conclusions: The development of added bacterial pneumonia increases the probability of death 2 times more, it amounts to 6 times more if there is antimicrobial resistance, it is observed to a greater extent for A. baumannii, K. pneumoniae and P. aeruginosa.

Indexed as

COVID-19Pneumonia, BacterialAnti-Bacterial AgentsCross-Sectional StudiesHumansMicrobial Sensitivity TestsPseudomonas aeruginosaStaphylococcus aureusAnti-Bacterial AgentsCoronavirus InfectionsMortalityPneumonia, Bacterial

Identifiers

PMID36282987
PMCPMC10395967
OpenAlexW4307431631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.